Home Quizzes Quiz Detail
Practice Quiz

ABIM Med Oncology Practice Questions - ABIM Medical Oncology Subspecialty Certification Exam

100 questions 5.0 rating Mobile friendly
$69.00

Unlock the full practice quiz

Get complete access to the questions, explanations and printable quiz resources.

Full access: unlock all quiz questions and explanations.
Printable review: access the full quiz PDF with correct answers after purchase.

About this Exam

Prepare with the ABIM Med Oncology Practice Questions - ABIM Medical Oncology Subspecialty Certification Exam practice quiz. This question bank includes 100 questions covering year-old, therapy, metastatic, cancer, and preferred. Use it to review important concepts, identify knowledge gaps, and build confidence for the related exam, course, or assessment.

Sample Questions

Question 1
A 54-year-old postmenopausal woman has a 2.2 cm, grade 2, ER 95%, PR 80%, HER2 0 by IHC, Ki-67 15% invasive ductal carcinoma with 1 of 3 sentinel nodes positive. Oncotype DX recurrence score is 18. In addition to breast-conserving therapy with whole-breast radiation, which adjuvant systemic therapy is most appropriate?
Dose-dense AC-T chemotherapy followed by endocrine therapy
Tamoxifen monotherapy for 10 years
Aromatase inhibitor (letrozole or anastrozole) for at least 5 years
Trastuzumab plus pertuzumab with endocrine therapy
Question 2
A 38-year-old premenopausal woman with a 3.5 cm, grade 3, ER 90%, PR 70%, HER2 0, node-positive (2/4) invasive lobular carcinoma completes AC-T chemotherapy. Based on SOFT/TEXT trials, what adjuvant endocrine therapy is most appropriate for this high-risk premenopausal patient?
Tamoxifen 20 mg daily for 5 years
Tamoxifen 20 mg daily for 10 years without ovarian suppression
Aromatase inhibitor (exemestane) plus ovarian function suppression (GnRH agonist) for 5 years
Aromatase inhibitor alone without ovarian suppression
Question 3
A 48-year-old woman with clinical stage II, ER 2%, PR 0%, HER2 0 (triple-negative) breast cancer is planned for neoadjuvant therapy. Based on KEYNOTE-522, which regimen is preferred?
AC followed by weekly paclitaxel, no immunotherapy
Carboplatin + paclitaxel followed by AC plus pembrolizumab, then adjuvant pembrolizumab
TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab)
Olaparib monotherapy
Question 4
A 62-year-old woman received neoadjuvant TCHP for clinical T2N1 HER2-positive breast cancer. Surgical pathology shows residual invasive disease in the breast (ypT1cN1). Which adjuvant therapy is most appropriate based on KATHERINE?
Continue trastuzumab + pertuzumab to complete 1 year
Trastuzumab emtansine (T-DM1) for 14 cycles
Trastuzumab deruxtecan (T-DXd)
Lapatinib plus capecitabine
Question 5
A 58-year-old woman with HR+/HER2-low (IHC 1+) metastatic breast cancer has progressed after two prior lines of chemotherapy in the metastatic setting. Which therapy demonstrated OS benefit in DESTINY-Breast04?
Sacituzumab govitecan
Trastuzumab deruxtecan (T-DXd)
Eribulin
Capecitabine

Ready to test your knowledge?

Buy Now to Access

Additional Information

ABIM Med Oncology Practice Questions - ABIM Medical Oncology Subspecialty Certification Exam

This practice set contains 100 questions from the matching question bank and focuses on year-old, therapy, metastatic, cancer, and preferred. Work through each question carefully, review the provided solutions, and revisit topics that need more study before your next attempt.

This is an independent study resource intended for practice and review; it is not an official examination or an endorsement by any organization named in the title.

Frequently Asked Questions

This quiz contains a total of 100 practice questions carefully selected to test your knowledge on this subject.
Yes, you will have exactly 0 minutes to complete the exam. A countdown timer will be visible once you start.
Yes, you can retake this practice test as many times as you need. The questions and options may be randomized on subsequent attempts to ensure comprehensive learning.

Reviews

5.0

Based on 0 reviews

Leave a Review

No reviews yet. Be the first to review!